Latest Leadership News

NOVONIX has advanced its position in the battery materials sector with a conditional US$754 million loan commitment from the U.S. Department of Energy and binding offtake agreements with automotive giants Stellantis and PowerCo. These milestones underpin its expansion plans for synthetic graphite production in North America.

Clarity Pharmaceuticals reports robust progress in its SECURE trial and secures FDA Fast Track Designation for its diagnostic agent 64Cu-SAR-bisPSMA, underpinning its growth and innovation in prostate cancer treatment.

First Au Limited updates on its Victorian and Western Australian gold exploration projects, announces key board changes, and completes a $325,000 capital raise to support ongoing operations.

Ionic Rare Earths reports strong progress on its Belfast rare earth oxide recycling facility, backed by a robust feasibility study and UK government grant applications, alongside strategic developments in Brazil and Uganda.

Papyrus Australia has taken significant strides in Q4 2024, signing a joint venture terms sheet in Vietnam, appointing new board members, and securing R&D tax incentives, positioning itself for expanded commercialization.

Lode Resources has completed the acquisition of the Montezuma Antimony Project in Tasmania, delivering high-grade drill results that bolster its strategy to become a leading Australian antimony producer amid global supply shortages.

Aspire Mining Limited has made significant strides in developing its Ovoot Coking Coal Project, progressing construction tenders and customer engagement despite a challenging coal market.

Kinetiko Energy reports mixed results from its five-well gas production test program, with the first well underperforming but the company maintaining optimism for the remaining wells and a strong financial footing.

Thunderbird Resources has significantly bolstered its portfolio with the acquisition of the Rockvale and Kookabookra antimony-gold projects in New South Wales, alongside promising uranium exploration results in Canada. These developments position the company for a dynamic 2025 exploration season.

Group 6 Metals Limited reveals a challenging quarter marked by safety incidents and production setbacks at its Dolphin Tungsten Mine, while initiating a major recapitalisation plan to stabilise finances and leadership.

Chimeric Therapeutics has dosed the first three patients in its Phase 1/2 CHM CDH17 CAR-T trial targeting gastrointestinal cancers, alongside advancing its AML and NK cell therapy programs. The company also secured $5 million in funding and appointed Dr Rebecca McQualter as CEO.

Andromeda Metals has made significant strides in advancing its Great White Project, progressing funding efforts for Stage 1A+ and securing key operational milestones. The company also bolstered its leadership with new board appointments and received a substantial tax refund, positioning it for a critical investment decision.